Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04774237 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

A Phase 2 study, sponsored by Visus Therapeutics.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target

NCT04774237 is a Phase 2 study that has completed, run by Visus Therapeutics. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04774237, a Phase 2 study, has completed, sponsored by Visus Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia

Interventions

  • DRUG BRIMOCHOL™
  • DRUG BRIMOCHOL™ F
  • DRUG Carbachol

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2021-03-24
Est. Completion 2021-10-19
Phase Phase 2

Sponsor

Visus Therapeutics

3 total trials

What the Registry Record Tells You About NCT04774237

The ClinicalTrials.gov registry entry for NCT04774237 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Visus Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which BRIMOCHOL™ is the first listed.

NCT04774237 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04774237 about?

NCT04774237 is a clinical study titled "Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia

What is the current status of trial NCT04774237?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-03-24. Estimated completion is 2021-10-19.

What interventions are being tested in trial NCT04774237?

The interventions under investigation include: BRIMOCHOL™ (DRUG), BRIMOCHOL™ F (DRUG), Carbachol (DRUG).

Who is sponsoring clinical trial NCT04774237?

This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.